[Dynamics of structural functional parameters of cardiovascular system in patients with Stable Angina and Congestive Heart Failure treated with Ivabradine for six months].
URGENCY: Frequency of warm reductions (FWR) is the independent risk factor increasing frequency of the general death rate, sudden death rate and death rate from cardiovascular diseases. Aim of the work was to study dynamics of parameters of cardiovascular system in Patients with Stable Angina (SA) and Congestive Heart Failure (CHF) treated with Ivabradin within six months were investigated.


METHODS
78 patients having symptoms of SA and CHF and also FWR more than 70 per 1 minute treated the maximum dose blokatorov, are divided into 2 groups. The patient of the first group (40 people) to standard therapy was added ivabradin. Patients of the second group (38 people) received the standard treatment of a SA and CHF. Before and after six months of the treatment the following findings were evaluated: the 6 minute walk test results, echocardiographic parameters, of heart rate variability (HRV), von Willebrand factor, endothelium dependent and independent vasodilation, main arteries rigidity.


RESULTS
The complex therapy including ivabradin, at examined patients promotes heart rate fall, to reduction of quantity of attacks of a stable angina and number of the accepted tablets of nitroglycerine, increase of CHF functional class, increase in shock volume left ventricular (LV) and certainly diastolichesky volume LV, to decrease in activity of the factor of Willebrand, quality of life. Indicators of HRV, endothelium dependent and independent vasodilation, main arteries rigidity during against 6 monthly therapies improve, but do not reach reliability degree.
N A
NA
Kosheleva
A P
AP
Rebrov
D000787:Angina Pectoris / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000009:adverse effects; D001552:Benzazepines / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004452:Echocardiography / Q000187:drug effects; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D004727:Endothelium / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D005080:Exercise Test / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D000077550:Ivabradine; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000378:metabolism
D000889:Anti-Arrhythmia Agents; D001552:Benzazepines; D014841:von Willebrand Factor; D000077550:Ivabradine